A Gene Transfer Study for Hemophilia A

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 26, 2017

Primary Completion Date

December 5, 2023

Study Completion Date

December 5, 2023

Conditions
Hemophilia A
Interventions
GENETIC

SPK-8011

A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene

Trial Locations (16)

2050

Royal Prince Alfred Hosptial, Camperdown

3004

The Alfred Hospital, Melbourne

10065

Weill Cornell Medicine-Comprehensive Center for Hemophilia and Coagulation Disorders, New York

10400

Mahidol University - Ramathibody Hospital, Bangkok

10733

Pennsylvania State University Milton S. Hershey Medical Center, Hershey

15213

Hemophilia Center of Western Pennsylvania, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

19107

Jefferson University Hospitals, Philadelphia

23219

Virginia Commonwealth University School of Medicine, Richmond

32610

University of Florida Health, Gainesville

39110

Mississippi Center for Advanced Medicine, Madison

94817

University of California Davis - Hemostasis and Thrombosis Center, Sacramento

97239

Oregon Health & Science University, Portland

526000

Chaim Sheba Center, Ramat Gan

02115

Boston Children's Hospital, Boston

L8N 3Z5

McMaster University Medical Centre and Juravinski Hospital, Hamilton

All Listed Sponsors
lead

Spark Therapeutics, Inc.

INDUSTRY

NCT03003533 - A Gene Transfer Study for Hemophilia A | Biotech Hunter | Biotech Hunter